PF-Atlas › Clinical Trials › NCT05951296
A Study to Investigate Leramistat in Patients With IPF
Leramistat · Phase 2
Registry ID
NCT05951296
Phase
Phase 2
Status
Withdrawn
Drug / intervention
Leramistat
Sponsor
Modern Biosciences Ltd
Start
2023-08-30
Locations
57
About this trial
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05951296 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.